hrp0095p1-496 | GH and IGFs | ESPE2022

The Effect of Anastrozole Treatment on Height Gain in Pubertal Boys on Growth Hormone Treatment

Tarçın Gürkan , Koç Çalışgan Cansu , Turan Hande , Ercan Oya

Introduction: In children receiving growth hormone (GH) therapy during puberty, epiphyseal fusion due to sex steroids often limits the height gain. Aromatase inhibitors may seem to help at this point despite the lack of evidence. Herein, it was aimed to investigate the efficacy of anastrozole for add-on treatment in pubertal male patients receiving GH therapy.Methods: This is a retrospective study comparing two groups of...

hrp0094p2-292 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Timing of infancy-childhood growth spurt in healthy Turkish children

Sharifova Sabina , Turan Hande , Tarcin Gurkan , Sharifli Samir , Gur Emel , Ercan Oya ,

Aim: The onset of the infancy-childhood growth spurt (IC spurt) is identical with the onset of the childhood component of the infancy-childhood-puberty growth model. The aim of this study was to determine the timing of IC spurt and to investigate the factors affecting it in healthy children.Materials and Methods: The files of 231 healthy children who were followed up regularly (at 0, 2, 4, 6, 12, 15, 18, 24, 30 and 36 months) at the Ista...

hrp0095p1-454 | Diabetes and Insulin | ESPE2022

Clinical and genetic evaluation of patients with maturity onset diabetes of the young (MODY) : Single center experience

Hande Turan , Bayramoglu Elvan , Gunes Kaya Didem , tarcin Gürkan , Bingöl Aydın Dilek , Ercan Oya , Evliyaoglu Olcay

Purpose: MODY is a monogenic diabetes with autosomal dominant inheritance that usually occurs in adolescence or young adulthood. It constitutes 1% of diabetes cases in childhood. The diagnosis of MODY is very difficult due to genetic heterogeneity, rarity, and clinical overlap with other diabetes types. In recent years, the diagnosis of MODY has become easier with genetic developments. On the other hand, misinterpretation of results can cause confusion. In thi...

hrp0095p1-457 | Diabetes and Insulin | ESPE2022

Rabson Mendenhall Syndrome: A Rare Insulin Resistance Syndrome

Bingöl Aydın Dilek , Tin Oğuzhan , Bayramoğlu Elvan , Turan Hande , Evliyaoğlu Olcay , Ercan Oya

Introduction: Rabson-Mendenhall Syndrome (RMS) is an autosomal recessive, extremely rare, serious insulin resistance syndrome that occurs as a result of mutation in the insulin receptor (INSR) gene. Pathogenic variants in the INSR gene cause a broad spectrum of inherited insulin resistance syndromes. Here, a male case who presented with the complaint of diffuse acanthosis nigricans and was diagnosed with RMS is shared. Case Repor...

hrp0089p2-p106 | Diabetes & Insulin P2 | ESPE2018

Congenital Hyperinsulinism: Clinical and Molecular Characteristics – Fluorine-18-L-Dihydroxyphenylalanine Positron Emission Tomography (F-DOPA PET) Scan Results – Treatment Responses and Short Term Outcomes of 5 Patients

Turan Hande , Dagdeviren Cakir Aydilek , Cayir Atilla , De Franco Elisa , Ellard Sian , Sonmezoglu Kerim , Ercan Oya , Olcay Evliyaoglu Saadet

Aim: The most common cause of persistent hypoglycemia and related brain damage in infancy is congenital hyperinsulinism (CHI), due to inappropriate secretion of insülin by pancreatic ╬▓cells. The most frequent and most serious mutations are activating mutations in ABBC8 or KCNJ11 genes. Genetic analyses, which might predict the type of lesion, performed in early period and 18f dopa pet scanning are very valuable for treatment choice and follow-up of the patients. In t...

hrp0095p1-475 | Fat, Metabolism and Obesity | ESPE2022

The Impact of Acute Exercise on 12,13-Dihydroxy-9Z-Octadecenoic Acid (12,13-DiHOME) Levels in Male Adolescents with Obesity

Ercan Oya , Gurup Aybüke , Tarçın Gürkan , Yakal Sertaç , Turan Hande , Şahinler Ayla Sibel , Boztürk Güngör Zeynep

Aim: 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) is a lipokine secreted from brown adipose tissue, and it is shown to have positive effects on dyslipidemia. Acute exercise have been shown to lead to an increase in its secretion. It was aimed to investigate the relation of 12,13-diHOME with obesity, exercise and dyslipidemia for the first time in the adolescent age group.Methods: This is a prospective study includ...

hrp0092p2-5 | Adrenals and HPA Axis | ESPE2019

Clinical Phenotype and Genotype Association in Patients with 21-hydroxylase Deficiency

Aghayeva Asmar , Turan Hande , Toksoy Guven , Dagdeviren Cakir Aydilek , Berkay Ezgi , Gunes Nilay , Evliyaoglu Olcay , Uyguner Zehra Oya , Dundar Munis , Tuysuz Beyhan , Ercan Oya

Introduction: Congenital adrenal hyperplasia (CAH) is an autosomal recessively transmitted disease and 95% of CAH cases are due to 21-hydroxylase deficiency (21-OHD). There are more than 100 mutations that cause CAH due to 21-OHD and the clinical expression of the disease is reported to correlate with mutated alleles.The aim: The aim of this study was to investigate responsible mutations and then to evaluate genotype...

hrp0095p1-578 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Results of Gonadotropin and Testosterone Treatments in Male Cases Diagnosed with Hypogonadotropic Hypogonadism: A Single Center Experience

Evliyaoğlu Olcay , Tarçın Gürkan , Dağdeviren Çakır Aydilek , Turan Hande , Özer Yavuz , Bingöl Aydın Dilek , Bayramoğlu Elvan , Ercan Oya

Purpose: Therapeutic goals in the adolescent male with hypogonadotropic hypogonadism(HH) are virilization, optimal adult height, normal bone mass, body composition, psychosocial development, and fertility. Until recently, only testosterone was used to treat adolescent males with HH. However, this treatment did not cover all treatment goals and adverse effects on fertility were reported. Therefore, gonadotropin therapy can be used in addition to testosterone in...

hrp0095p1-99 | GH and IGFs | ESPE2022

Survey to Investigate Adherence to Growth Hormone Treatment in Children: The Impact of COVID-19 Pandemic

Eren Erdal , Cetinkaya Semra , Denkboy Ongen Yasemin , Tercan Ummuhan , Darcan Sukran , Turan Hande , Aydin Murat , Yavuz Yilmaz Fatma , Kilci Fatih , Sever Eklioglu Beray , Hatipoglu Nihal , Yuksek Acinikli Kubra , Orbak Zerrin , Camtosun Emine , Savas Erdeve Senay , Arslan Emrullah , Ercan, Feyza Darendeliler Oya

Introduction: Treatment adherence is crucial for the success of Growth Hormone (GH) therapy. Non-adherence rates have varied over a wide range from 5% to 80% in the literature. Several factors may have an impact on treatment adherence. Besides, with the COVID-19 pandemic that affected the whole world, there were problems with the hospital admission and routine controls of the patients who used GH treatment.Objective: The...